At a price of up to $10 billion, Pfizer has claimed victory in its bidding war against Novo Nordisk to acquire Metsera. It's ...

Pfizer has secured a $10 billion acquisition of obesity drug developer Metsera, outbidding rival Novo Nordisk in a heated ...

On November 4, 2025, just a day after Pfizer filed its suits against Novo Nordisk and Metsera, Novo Nordisk submitted an ...

COPENHAGEN (Reuters) -Shares in Novo Nordisk rose on Monday after the Wegovy maker lost out to Pfizer in a $10 billion ...

Pfizer secures a $10B deal to buy Metsera, ending its fierce bidding war with Novo Nordisk and reigniting its push into the obesity market.

Pfizer Is Buying Weight-Loss Drugmaker Metsera. Why Novo Nordisk Is the Real Winner.

Metsera said it has struck a revised merger agreement with Pfizer that values the company at up to $86.25 per share in cash.

Pharmaceutical giant Pfizer has finally acquired development-stage obesity drugmaker Metsera Inc., in an intense bidding war against the Danish drugmaker Novo Nordisk for over $10 billion.

The contract chip maker's sales rose last month at the slowest pace since February 2024, but [remained in double-digits]( ...

Pfizer prevails 10B bidding for Metsera, securing a deal to expand its obesity drug portfolio with innovative weight-loss treatments.

Pharma giant had to pay a blockbuster price to buy Metsera after the biotech prospect spurred an auction with Novo Nordisk ...

Pfizer Inc. acquires Metsera, Inc., beating Novo Nordisk, for up to $86.25/share. Click for my analysis of the deal and what ...